SynthesisSexually transmitted infections2006
Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.
Synthesis in Sexually transmitted infections, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Evaluation of Chlamydia trachomatis screening from the perspective of health economics: a systematic review.Frontiers in public health · 2023Pooled it
- What is the effectiveness of community-based health promotion campaigns on chlamydia screening uptake in young people and what barriers and facilitators have been identified? A mixed-methods systematic review.Sexually transmitted infections · 2022Pooled it
- How robust are the natural history parameters used in chlamydia transmission dynamic models? A systematic review.Theoretical biology & medical modelling · 2014Pooled it
- Chlamydia prevalence in the general population: is there a sex difference? a systematic review.BMC infectious diseases · 2013Pooled it
- One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations.Sexually transmitted infections · 2007Pooled it
- Young, deprived women are more at risk of testing positive for Chlamydia trachomatis: Results from a cross-sectional multicentre study in French health examination centres.Public health in practice (Oxford, England) · 2024Article
- Financing care for Severe Stigmatizing Skin Diseases (SSSDs) in Liberia: challenges and opportunities.International journal for equity in health · 2022Article
- Evaluation of the Predictive Value of Urine Leukocyte Esterase Test inFrontiers in medicine · 2022Article
- Article
- Optimizing strategies for population-based chlamydia infection screening among young women: an age-structured system dynamics approach.BMC public health · 2015Article
- Cost-effectiveness of screening men in Maricopa County jails for chlamydia and gonorrhea to avert infections in women.Sexually transmitted diseases · 2013Article
- Chlamydia trachomatis infection among women 26 to 39 years of age in the United States, 1999 to 2010.Sexually transmitted diseases · 2013Article
- Health economic and infectious disease modelling: a guide to merging streams.PharmacoEconomics · 2011Article
- Modelling the epidemiology of infectious diseases for decision analysis: a primer.PharmacoEconomics · 2011Review
- Screening young adults for prevalent chlamydial infection in community settings.Annals of epidemiology · 2008Article
- Costs and health consequences of chlamydia management strategies among pregnant women in sub-Saharan Africa.Sexually transmitted infections · 2007Article
- Cost effectiveness of one to one STI prevention interventions.Sexually transmitted infections · 2007Article
- Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project.BMJ (Clinical research ed.) · 2007Article
- The cost effectiveness of opportunistic chlamydia screening in England.Sexually transmitted infections · 2007Article
- Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review systematically and critically, evidence used to derive estimates of costs and cost effectiveness of chlamydia screening.
methodsSystematic review. A search of 11 electronic bibliographic databases from the earliest date available to August 2004 using keywords including chlamydia, pelvic inflammatory disease, economic evaluation, and cost. We included studies of chlamydia screening in males and/or females over 14 years, including studies of diagnostic tests, contact tracing, and treatment as part of a screening programme. Outcomes included cases of chlamydia identified and major outcomes averted. We assessed methodological quality and the modelling approach used.
resultsOf 713 identified papers we included 57 formal economic evaluations and two cost studies. Most studies found chlamydia screening to be cost effective, partner notification to be an effective adjunct, and testing with nucleic acid amplification tests, and treatment with azithromycin to be cost effective. Methodological problems limited the validity of these findings: most studies used static models that are inappropriate for infectious diseases; restricted outcomes were used as a basis for policy recommendations; and high estimates of the probability of chlamydia associated complications might have overestimated cost effectiveness. Two high quality dynamic modelling studies found opportunistic screening to be cost effective but poor reporting or uncertainty about complication rates make interpretation difficult.
conclusionThe inappropriate use of static models to study interventions to prevent a communicable disease means that uncertainty remains about whether chlamydia screening programmes are cost effective or not. The results of this review can be used by health service managers in the allocation of resources, and health economists and other researchers who are considering further research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.